RU99113031A - EPOTILONS C, D, E AND F, THEIR RECEIVING AND MEANS ON THEIR BASIS - Google Patents
EPOTILONS C, D, E AND F, THEIR RECEIVING AND MEANS ON THEIR BASISInfo
- Publication number
- RU99113031A RU99113031A RU99113031/04A RU99113031A RU99113031A RU 99113031 A RU99113031 A RU 99113031A RU 99113031/04 A RU99113031/04 A RU 99113031/04A RU 99113031 A RU99113031 A RU 99113031A RU 99113031 A RU99113031 A RU 99113031A
- Authority
- RU
- Russia
- Prior art keywords
- epothilone
- biotransformant
- culture
- representing
- fact
- Prior art date
Links
- 229930013356 epothilones Natural products 0.000 claims 15
- XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000011347 resin Substances 0.000 claims 4
- 229920005989 resin Polymers 0.000 claims 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 239000012050 conventional carrier Substances 0.000 claims 2
- 239000000287 crude extract Substances 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 claims 1
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 claims 1
- HESCAJZNRMSMJG-KKQRBIROSA-N (1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-5,7,9,9-tetramethyl-14-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N Epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims 1
- QXRSDHAAWVKZLJ-TYFQHMATSA-N Epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@@]2(C)CCC[C@@H]([C@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-TYFQHMATSA-N 0.000 claims 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N Epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 claims 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 claims 1
- XOZIUKBZLSUILX-UKMAFROXSA-N Epothilone D Chemical compound O1C(=O)C[C@@H](O)C(C)(C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)CCC\C(C)=C/C[C@@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-UKMAFROXSA-N 0.000 claims 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 claims 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N Epothilone E Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 claims 1
- UKIMCRYGLFQEOE-RGJAOAFDSA-N Epothilone F Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 claims 1
- 241000862997 Sorangium cellulosum Species 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 229930013357 epothilone A Natural products 0.000 claims 1
- 229930013349 epothilone B Natural products 0.000 claims 1
- 229930013351 epothilone C Natural products 0.000 claims 1
- 229930013353 epothilone D Natural products 0.000 claims 1
- 229930013354 epothilone E Natural products 0.000 claims 1
- 229930013311 epothilone F Natural products 0.000 claims 1
- 238000010413 gardening Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000004476 plant protection product Substances 0.000 claims 1
- 238000010791 quenching Methods 0.000 claims 1
- 230000000171 quenching Effects 0.000 claims 1
Claims (19)
где R = Н, СН3.1. Epothilone General formula
where R = H, CH 3 .
где R = Н, СН3.6. Epothilone of General Formula
where R = H, CH 3 .
а) культивированием микроорганизма Sorangium cellulosum DSM 6773 в присутствии адсорбирующей смолы известным образом, отделением культуры от адсорбирующей смолы и, в случае необходимости, добавлением ко всему количеству или к части отделенной культуры метанольного раствора исходного эпотилона,
б) инкубированием культуры с добавленным эпотилоном с последующим добавлением адсорбирующей смолы,
в) отделением адсорбирующей смолы от культуры элюированием метанолом и концентрированием элюата до получения сырого экстракта,
г) разделением сырого экстракта этилацетатом и водой, отделением этилацетатной фазы с последующим ее концентрированием до получения масла,
д) хроматографией масла на обращенной фазе при следующих условиях:
материал колонки - Нуклеосил 100 С-18, 7 мкм
размеры колонки - 250 х 4 мм
растворитель - метанол/вода = 60 : 40
скорость протекания растворителя - 1,2 мл/мин
с последующим отделением содержащих биотрансформант фракций, детектируемых гашением флуоресценции при 254 нм, и выделением биотрансформанта.11. Biotransformant epothilones obtained
a) cultivating the microorganism Sorangium cellulosum DSM 6773 in the presence of an adsorbing resin in a known manner, separating the culture from the adsorbing resin and, if necessary, adding to the whole or part of the separated culture a methanol solution of the starting epothilone,
b) incubating the culture with added epothilone followed by the addition of an adsorbent resin,
c) separating the adsorption resin from the culture by elution with methanol and concentrating the eluate to obtain a crude extract,
g) separation of the crude extract with ethyl acetate and water, separating the ethyl acetate phase, followed by concentration to an oil,
e) reverse phase oil chromatography under the following conditions:
column material - Nucleosil 100 C-18, 7 microns
column dimensions - 250 x 4 mm
solvent - methanol / water = 60: 40
solvent flow rate 1.2 ml / min
with the subsequent separation of fractions containing biotransformant, detected by quenching of fluorescence at 254 nm, and release of biotransformant.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19647580 | 1996-11-18 | ||
DE19647580.5 | 1996-11-18 | ||
DE19707506.1 | 1997-02-25 | ||
DE19707506 | 1997-02-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99113031A true RU99113031A (en) | 2001-04-27 |
RU2198173C2 RU2198173C2 (en) | 2003-02-10 |
Family
ID=26031383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99113031/04A RU2198173C2 (en) | 1996-11-18 | 1997-11-18 | Epotylones c, d, e and f, their synthesis and agents based on thereof |
Country Status (24)
Country | Link |
---|---|
US (6) | US7067544B2 (en) |
EP (2) | EP1367057B1 (en) |
JP (1) | JP4274583B2 (en) |
KR (1) | KR100538095B1 (en) |
CN (2) | CN100344627C (en) |
AT (2) | ATE408612T1 (en) |
AU (1) | AU753546B2 (en) |
BR (1) | BR9713363B1 (en) |
CA (1) | CA2269118C (en) |
CY (1) | CY2542B1 (en) |
CZ (2) | CZ296164B6 (en) |
DE (2) | DE59712968D1 (en) |
DK (2) | DK1367057T3 (en) |
ES (2) | ES2312695T3 (en) |
HK (2) | HK1022314A1 (en) |
HU (1) | HU229833B1 (en) |
IL (1) | IL129558A (en) |
NO (1) | NO319984B1 (en) |
NZ (1) | NZ335383A (en) |
PL (1) | PL193229B1 (en) |
PT (2) | PT941227E (en) |
RU (1) | RU2198173C2 (en) |
TW (1) | TW408119B (en) |
WO (1) | WO1998022461A1 (en) |
Families Citing this family (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997019086A1 (en) | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, preparation and use |
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
EP1367057B1 (en) * | 1996-11-18 | 2008-09-17 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilones E and F |
AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (en) | 1998-02-25 | 2003-02-21 | Novartis Ag | USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
DE19820599A1 (en) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | New epothilone derivatives useful as pharmaceuticals and in plant protection |
NZ508326A (en) * | 1998-06-18 | 2003-10-31 | Novartis Ag | A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B |
DE19826988A1 (en) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilone minor components |
DE19846493A1 (en) * | 1998-10-09 | 2000-04-13 | Biotechnolog Forschung Gmbh | DNA sequence coding for products involved in the biosynthesis of polyketide or heteropolyketide compounds, especially epothilone |
KR100851418B1 (en) | 1998-11-20 | 2008-08-08 | 코산 바이오사이언시즈, 인코포레이티드 | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
WO2000039276A2 (en) * | 1998-12-23 | 2000-07-06 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
AU771089B2 (en) * | 1999-02-22 | 2004-03-11 | Bristol-Myers Squibb Company | C-21 modified epothilones |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
BR0009721A (en) | 1999-04-15 | 2002-02-13 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
EP2266607A3 (en) | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
US6998256B2 (en) | 2000-04-28 | 2006-02-14 | Kosan Biosciences, Inc. | Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate |
US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
CA2404938C (en) * | 2000-04-28 | 2011-11-01 | Kosan Biosciences, Inc. | Production of polyketides |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
GB0029895D0 (en) | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
ATE389401T1 (en) | 2001-01-25 | 2008-04-15 | Bristol Myers Squibb Co | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING EPOTHILONE ANALOGS FOR CANCER TREATMENT |
NZ526871A (en) * | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
EP1353667A1 (en) | 2001-01-25 | 2003-10-22 | Bristol-Myers Squibb Company | Parenteral formulations containing epothilone analogs |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
JP2004522771A (en) | 2001-02-20 | 2004-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | Epothilone derivatives for the treatment of refractory tumors |
MXPA03007394A (en) | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Treatment of refractory tumors using epothilone derivatives. |
NZ527764A (en) | 2001-02-27 | 2006-01-27 | Novartis Ag | Combination comprising a signal transduction inhibitor and an epothilone derivative |
ATE325201T1 (en) | 2001-02-27 | 2006-06-15 | Biotechnolog Forschung Gmbh | DEGRADATION OF EPOTHILONES AND ETHYNYL SUBSTITUTED EPOTHILONES |
WO2002072085A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
JP2004532888A (en) | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | Epothilone derivative |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
US6884608B2 (en) | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
MXPA04006822A (en) | 2002-01-14 | 2004-12-08 | Novartis Ag | Combinations comprising epothilones and anti-metabolites. |
TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
ATE452896T1 (en) | 2002-03-12 | 2010-01-15 | Bristol Myers Squibb Co | C3-CYANOEPOTHILONE DERIVATIVES |
AU2003218107A1 (en) | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
AU2003243561A1 (en) | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
CA2494742C (en) * | 2002-07-29 | 2015-05-12 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
JP4791183B2 (en) * | 2002-08-23 | 2011-10-12 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | Synthesis and use of epothilone, its intermediates and analogues |
RS20050235A (en) * | 2002-09-23 | 2007-06-04 | Bristol Myers Squibb Company, | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
AU2003267751A1 (en) * | 2002-10-15 | 2004-05-04 | Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College | Use of epothilone derivatives for the treatment of hyperparathyroidism |
EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | Open chain prolyl urea-related modulators of androgen receptor function |
CN101177425B (en) * | 2003-01-28 | 2012-07-18 | 北京华昊中天生物技术有限公司 | Novel epothilones compound as well as preparation method and use thereof |
US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
EP1559447A1 (en) | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
JP4691549B2 (en) | 2004-04-07 | 2011-06-01 | ノバルティス アーゲー | Inhibitors of IAP |
US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
CA2588400A1 (en) * | 2004-11-18 | 2006-05-26 | Bristol-Myers Squibb Company | Enteric coated bead comprising ixabepilone, and preparation thereof |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JP2009510073A (en) | 2005-09-27 | 2009-03-12 | ノバルティス アクチエンゲゼルシャフト | Carboxyamine compounds and methods of use thereof |
ES2481671T3 (en) | 2005-11-21 | 2014-07-31 | Novartis Ag | MTOR inhibitors in the treatment of endocrine tumors |
GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
WO2007117439A2 (en) | 2006-03-31 | 2007-10-18 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP2314297A1 (en) | 2006-04-05 | 2011-04-27 | Novartis AG | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
RU2447891C2 (en) | 2006-04-05 | 2012-04-20 | Новартис Аг | Combinations of therapeutic agents applicable for treating cancer |
CA2649792A1 (en) | 2006-05-09 | 2007-11-15 | Novartis Ag | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
ATE502943T1 (en) | 2006-09-29 | 2011-04-15 | Novartis Ag | PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS |
BRPI0718360A2 (en) | 2006-12-04 | 2013-11-12 | Univ Illinois | "COMPOSITIONS AND METHODS FOR CANCER TREATMENT WITH COUPREDOXINS AND RICH DNA IN CPG" |
WO2008098216A2 (en) | 2007-02-08 | 2008-08-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
AU2008216327A1 (en) | 2007-02-15 | 2008-08-21 | Novartis Ag | Combination of LBH589 with other therapeutic agents for treating cancer |
ES2524259T3 (en) | 2008-03-24 | 2014-12-04 | Novartis Ag | Aryl sulfonamide matrix metalloproteinase inhibitors |
WO2009118305A1 (en) | 2008-03-26 | 2009-10-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases b |
CN101362784A (en) * | 2008-10-06 | 2009-02-11 | 山东大学 | Ebomycin glycosides compounds, composition using the same as activity component and use thereof |
WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
MY155570A (en) | 2009-06-26 | 2015-10-30 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
EA201200260A1 (en) | 2009-08-12 | 2012-09-28 | Новартис Аг | HETEROCYCLIC HYDRAZONES AND THEIR APPLICATION FOR THE TREATMENT OF CANCER AND INFLAMMATION |
EA201200318A1 (en) | 2009-08-20 | 2012-09-28 | Новартис Аг | Heterocyclic oximes |
US20120149661A1 (en) | 2009-08-26 | 2012-06-14 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
CN102596951B (en) | 2009-11-04 | 2015-04-15 | 诺华股份有限公司 | Heterocyclic sulfonamide derivatives useful as MEK inhibitors |
GEP20135998B (en) | 2009-12-08 | 2013-12-25 | Novartis Ag | Heterocyclic sulfonamide derivatives |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CU24130B1 (en) | 2009-12-22 | 2015-09-29 | Novartis Ag | ISOQUINOLINONES AND REPLACED QUINAZOLINONES |
AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
UA112517C2 (en) | 2010-07-06 | 2016-09-26 | Новартіс Аг | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
EP2665493B1 (en) | 2011-01-20 | 2018-03-21 | Board Of Regents, The University Of Texas System | Mri markers, delivery and extraction systems, and methods of manufacture and use thereof |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2702052B1 (en) | 2011-04-28 | 2017-10-18 | Novartis AG | 17alpha-hydroxylase/c17,20-lyase inhibitors |
CA2838029A1 (en) | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
EA201490164A1 (en) | 2011-06-27 | 2014-04-30 | Новартис Аг | SOLID FORMS AND SALTS DERIVATIVES OF TETRAHYDROPYRIDOPYRIMIDINE |
CN102863474A (en) | 2011-07-09 | 2013-01-09 | 陈小平 | Platinum compounds for treating cell proliferative diseases and preparation method and application thereof |
MX339302B (en) | 2011-09-15 | 2016-05-19 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase. |
CN102993239A (en) | 2011-09-19 | 2013-03-27 | 陈小平 | Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino |
US8969341B2 (en) | 2011-11-29 | 2015-03-03 | Novartis Ag | Pyrazolopyrrolidine compounds |
LT2794600T (en) | 2011-12-22 | 2018-02-26 | Novartis Ag | 2,3-dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (pi3k) inhibitors for the treatment of e.g. rheumatoid arthritis |
EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
EP2794592A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
JP2015503517A (en) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Compound for inhibiting interaction between BCL2 and binding partner |
EP2794591A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
JP2015503516A (en) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Compound for inhibiting interaction between BCL2 and binding partner |
AU2012355613A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
KR101372563B1 (en) * | 2011-12-26 | 2014-03-14 | 주식회사 삼양바이오팜 | Method of isolating and purifying epothilone A and B from epothilone containing material |
UY34591A (en) | 2012-01-26 | 2013-09-02 | Novartis Ag | IMIDAZOPIRROLIDINONA COMPOUNDS |
MX2014013373A (en) | 2012-05-15 | 2015-08-14 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1. |
KR20150008406A (en) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
PT2900637T (en) | 2012-05-15 | 2017-11-15 | Novartis Ag | Thiazole or imidazole substituted pyrimidine, pyridine and pyrazine amide derivatives and related compounds as abl1, abl2 and bcr-abl1 inhibitors for the treatment of cancer, specific viral infections and specific cns disorders |
AP3613A (en) | 2012-05-15 | 2016-02-29 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1 |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
BR112014031421A2 (en) | 2012-06-15 | 2017-06-27 | Brigham & Womens Hospital Inc | cancer treatment compositions and methods for producing them |
SI3023415T1 (en) | 2012-10-02 | 2018-01-31 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
US9725477B2 (en) | 2012-11-17 | 2017-08-08 | Beijing Fswelcome Technology Development Co., Ltd | Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino |
TW201422625A (en) | 2012-11-26 | 2014-06-16 | Novartis Ag | Solid form of dihydro-pyrido-oxazine derivative |
AU2013359506B2 (en) | 2012-12-10 | 2018-05-24 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
JO3464B1 (en) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | Compositions of Tiacumicin Compounds |
US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
BR112015020650A2 (en) | 2013-02-27 | 2017-07-18 | Epitherapeutics Aps | histone demethylase inhibitors |
US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
KR20160018534A (en) | 2013-06-11 | 2016-02-17 | 바이엘 파마 악티엔게젤샤프트 | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
UY35675A (en) | 2013-07-24 | 2015-02-27 | Novartis Ag | SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
MY184292A (en) | 2013-09-22 | 2021-03-30 | Sunshine Lake Pharma Co Ltd | Substituted aminopyrimidine compounds and methods of use |
KR102355745B1 (en) | 2013-10-11 | 2022-01-26 | 아사나 바이오사이언시스 엘엘씨 | Protein-polymer-drug conjugates |
KR102087850B1 (en) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | Protein-Polymer-Drug Conjugates |
CA2943979A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
EP3126345A1 (en) | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
US10426753B2 (en) | 2014-04-03 | 2019-10-01 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
EA201790154A1 (en) | 2014-08-27 | 2017-08-31 | Джилид Сайэнс, Инк. | COMPOUNDS AND METHODS FOR INHIBITING HISTONAL DEMETYLASES |
EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
EP3474901A1 (en) | 2016-06-27 | 2019-05-01 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
US10772971B2 (en) | 2017-06-22 | 2020-09-15 | Mersana Therpeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
EP3788032B1 (en) | 2018-05-04 | 2024-01-24 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
CA3099419A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
US20230021500A1 (en) | 2018-10-29 | 2023-01-26 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
FR3087650B1 (en) | 2018-10-31 | 2021-01-29 | Bio Even | FLAVINE ADENINE DINUCLEOTIDE (FAD) FOR USE FOR THE PREVENTION AND / OR TREATMENT OF CANCER |
IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for high click release speed and yield |
CN115135628A (en) | 2019-06-17 | 2022-09-30 | 泰克沃尔科斯制药有限公司 | Compounds for fast and efficient click release |
CA3230774A1 (en) | 2021-09-06 | 2023-03-09 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023104941A1 (en) | 2021-12-08 | 2023-06-15 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
WO2023158305A1 (en) | 2022-02-15 | 2023-08-24 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
WO2024080872A1 (en) | 2022-10-12 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Strained bicyclononenes |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0358606A3 (en) | 1988-09-09 | 1990-10-31 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Microbiological method for the preparation of agrochemically useful macrocyclic lactone derivatives with a microbicidal activity |
GB8909737D0 (en) * | 1989-04-27 | 1989-06-14 | Shell Int Research | Thiazole derivatives |
DE4138042C2 (en) * | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilones, their production processes and agents containing these compounds |
EP0687174B1 (en) * | 1993-03-05 | 2001-06-13 | Hexal Ag | Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation |
WO1995018798A1 (en) * | 1994-01-11 | 1995-07-13 | The Scripps Research Institute | Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms |
DE19639456A1 (en) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | New epothilone derivatives |
WO1997019086A1 (en) | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, preparation and use |
DE19542986A1 (en) * | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | New epothilone derivatives useful as cytostatics |
DE19645362A1 (en) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Production of epothilone compounds with taxol-like activity |
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
WO1998008849A1 (en) * | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Method for producing epothilones, and intermediate products obtained during the production process |
DE19636343C1 (en) | 1996-08-30 | 1997-10-23 | Schering Ag | New (di:methyl)-dioxanyl-methyl-pentanone and related compounds |
DE19645361A1 (en) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Production of epothilone compounds with taxol-like activity |
EP1367057B1 (en) | 1996-11-18 | 2008-09-17 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilones E and F |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
AU756699B2 (en) * | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (en) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | New beta-keto-alcohol derivatives |
WO1998038192A1 (en) * | 1997-02-25 | 1998-09-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilones with a modified side chain |
US5828449A (en) | 1997-02-26 | 1998-10-27 | Acuity Imaging, Llc | Ring illumination reflective elements on a generally planar surface |
DE19713970B4 (en) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone Synthesis Building Blocks II - Prenyl Derivatives |
ATE225783T1 (en) | 1997-04-18 | 2002-10-15 | Studiengesellschaft Kohle Mbh | SELECTIVE OLEFIN METATHESIS OF BI- OR POLYFUNCTIONAL SUBSTRATES IN COMPRESSED CARBON DIOXIDE AS A REACTION MEDIUM |
DE19821954A1 (en) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Preparation of epothilone derivatives |
DE19720312A1 (en) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Preparation with increased in vivo tolerance |
DE19726627A1 (en) | 1997-06-17 | 1998-12-24 | Schering Ag | New intermediates for epothilone |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
ATE224882T1 (en) | 1997-07-16 | 2002-10-15 | Schering Ag | THIAZOLE DERIVATIVES, METHOD OF PRODUCTION AND USE |
AU9340998A (en) | 1997-08-09 | 1999-03-01 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
ES2324378T3 (en) | 1998-02-05 | 2009-08-05 | Novartis Ag | PHARMACEUTICAL COMPOSITION CONTAINING EPOTILONE. |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
EP1058679B1 (en) | 1998-02-25 | 2005-10-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
FR2775187B1 (en) | 1998-02-25 | 2003-02-21 | Novartis Ag | USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT |
DE19826988A1 (en) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilone minor components |
WO2000000485A1 (en) | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
KR100851418B1 (en) | 1998-11-20 | 2008-08-08 | 코산 바이오사이언시즈, 인코포레이티드 | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6410301B1 (en) * | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
ATE248175T1 (en) | 1998-12-22 | 2003-09-15 | Novartis Pharma Gmbh | EPOTHILONE DERIVATIVES AND THEIR USE AS ANTI-TUMOR AGENTS |
US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6596875B2 (en) * | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
IL144519A0 (en) | 1999-02-18 | 2002-05-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
AU771089B2 (en) * | 1999-02-22 | 2004-03-11 | Bristol-Myers Squibb Company | C-21 modified epothilones |
US6211412B1 (en) * | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
PE20010116A1 (en) | 1999-04-30 | 2001-02-15 | Schering Ag | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTILONE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US6489314B1 (en) * | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US6589968B2 (en) * | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
US6906188B2 (en) * | 2001-04-30 | 2005-06-14 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Method for synthesizing epothilones and epothilone analogs |
WO2003029195A1 (en) * | 2001-09-28 | 2003-04-10 | Sumika Fine Chemicals Co., Ltd. | Intermediates for epothilone derivative and process for producing these |
US6884608B2 (en) * | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
US6921769B2 (en) * | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
RS20050235A (en) | 2002-09-23 | 2007-06-04 | Bristol Myers Squibb Company, | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
-
1997
- 1997-11-18 EP EP03016552A patent/EP1367057B1/en not_active Expired - Lifetime
- 1997-11-18 NZ NZ335383A patent/NZ335383A/en not_active IP Right Cessation
- 1997-11-18 PT PT97951233T patent/PT941227E/en unknown
- 1997-11-18 CN CNB2005100062827A patent/CN100344627C/en not_active Expired - Lifetime
- 1997-11-18 CZ CZ0175099A patent/CZ296164B6/en not_active IP Right Cessation
- 1997-11-18 RU RU99113031/04A patent/RU2198173C2/en active
- 1997-11-18 AT AT03016552T patent/ATE408612T1/en active
- 1997-11-18 IL IL12955897A patent/IL129558A/en not_active IP Right Cessation
- 1997-11-18 PL PL333435A patent/PL193229B1/en unknown
- 1997-11-18 WO PCT/EP1997/006442 patent/WO1998022461A1/en active IP Right Grant
- 1997-11-18 AT AT97951233T patent/ATE267197T1/en active
- 1997-11-18 PT PT03016552T patent/PT1367057E/en unknown
- 1997-11-18 DE DE59712968T patent/DE59712968D1/en not_active Expired - Lifetime
- 1997-11-18 EP EP97951233A patent/EP0941227B2/en not_active Expired - Lifetime
- 1997-11-18 ES ES03016552T patent/ES2312695T3/en not_active Expired - Lifetime
- 1997-11-18 BR BRPI9713363-9A patent/BR9713363B1/en not_active IP Right Cessation
- 1997-11-18 KR KR10-1999-7004302A patent/KR100538095B1/en not_active IP Right Cessation
- 1997-11-18 HU HU0000497A patent/HU229833B1/en unknown
- 1997-11-18 ES ES97951233T patent/ES2221692T5/en not_active Expired - Lifetime
- 1997-11-18 CN CNB971998140A patent/CN1196698C/en not_active Expired - Lifetime
- 1997-11-18 AU AU54837/98A patent/AU753546B2/en not_active Expired
- 1997-11-18 DK DK03016552T patent/DK1367057T3/en active
- 1997-11-18 DE DE59711647T patent/DE59711647D1/en not_active Expired - Lifetime
- 1997-11-18 CZ CZ20041118A patent/CZ303422B6/en not_active IP Right Cessation
- 1997-11-18 JP JP52320898A patent/JP4274583B2/en not_active Expired - Lifetime
- 1997-11-18 CA CA2269118A patent/CA2269118C/en not_active Expired - Lifetime
- 1997-11-18 DK DK97951233T patent/DK0941227T5/en active
-
1998
- 1998-01-21 TW TW086117334A patent/TW408119B/en not_active IP Right Cessation
-
1999
- 1999-05-14 NO NO19992338A patent/NO319984B1/en not_active IP Right Cessation
-
2000
- 2000-02-29 HK HK00101272A patent/HK1022314A1/en not_active IP Right Cessation
-
2004
- 2004-11-12 US US10/988,328 patent/US7067544B2/en not_active Expired - Fee Related
-
2005
- 2005-10-26 CY CY0500058A patent/CY2542B1/en unknown
-
2006
- 2006-03-24 HK HK06103757A patent/HK1083832A1/en not_active IP Right Cessation
- 2006-04-27 US US11/412,536 patent/US20060264482A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/110,781 patent/US20080293784A1/en not_active Abandoned
-
2009
- 2009-03-24 US US12/409,823 patent/US7846952B2/en not_active Expired - Fee Related
- 2009-05-01 US US12/434,078 patent/US7759375B2/en not_active Expired - Fee Related
-
2010
- 2010-12-06 US US12/961,447 patent/US8076490B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99113031A (en) | EPOTILONS C, D, E AND F, THEIR RECEIVING AND MEANS ON THEIR BASIS | |
CZ175099A3 (en) | C, d, e, and f epothiolones, process of their preparation and their use as cytostatics and preparations for protecting plants | |
Anke et al. | Antibiotics from basidiomycetes. XVIII strobilurin C and oudemansin B, two new antifungal metabolites from Xerula species (Agaricales) | |
RU2285007C2 (en) | Method for isolating epotilons from reaction mixture and desorption from synthetic resin (variants), using low-polar or nonpolar solvent for realization of method | |
Nakagawa et al. | Structure of viridenomycin | |
Leutou et al. | New production of antibacterial polycyclic quinazoline alkaloid, thielaviazoline, from anthranilic acid by the marine-mudflat-derived fungus Thielavia sp. | |
EP1392669B1 (en) | Chromatographic separation method of paclitaxel and cephalomannin | |
Takahashi et al. | Enantioselective total synthesis of cineromycin B | |
Matsuo et al. | Squalene‐derived triterpene polyethers from the red alga Laurencia omaezakiana | |
Zhou et al. | New limonoids from Melia toosendan | |
Miyaoka et al. | Synthesis and structural revision of marine eicosanoid agardhilactone | |
Srinivas et al. | Two new tetracyclic triterpenes from the heartwood of Ailanthus excelsa Roxb. | |
Tori et al. | New oplopane-type sesquiterpenoids from Ligularia duciformis | |
NZ230596A (en) | Soraphen derivatives, myxobacteria which produce them, and their use for combatting plant diseases | |
Chang et al. | Secondary metabolites from the stem bark of Litsea akoensis and their cytotoxic activity | |
Schoettler et al. | Isolation and characterization of two verrucarins from Myrothecium roridum | |
Venugopalan et al. | Role of radical initiated cyclisation reactions in the synthesis of artemisinin based novel ring skeletons. | |
Akasaka et al. | Fascicularones H–K, Four New Sesquiterpenoids from the Cultured Mycelia of the Fungus Hypholoma fasciculare | |
Xu et al. | Two dibenzoquinones from the fungus Acremonium cavaraeanum | |
Kong | Novel nitrogenous metabolites from marine sponges | |
KR20050019892A (en) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents | |
MUNK et al. | Bhimamycin A~ E and Bhimanone: Isolation, Structure Elucidation and Biological Ac-tivity of Novel Quinone Antibiotics from a Terrestrial Streptomycete |